RxDoctor Payments Data

Thomas Selvaggi, MD

Allergy/ Immunology · Hackensack, NJNPI 1083664197

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $10,275 of the $11,605 with a category attached, or 88.5%. Pfizer accounts for 97.0% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $5,712 and has fallen 99.0% since, to $59 in 2025.

$11,605in general payments, 2019–2025

Across 24 payments — averaging $483.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$11K
  • AbbVie$191
  • Regeneron Healthcare Solutions, Inc.$39
  • Teva Pharmaceuticals USA, Inc.$36
  • CSL Behring$36
  • Boehringer Ingelheim$30
  • plus $23 from 2 others

What the payments were for

  • Speaking & faculty fees$10,27589%
  • Travel & lodging$4584%
  • Food & beverage$8017%
  • Education$711%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy/ immunology providers in New Jerseyto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$59,137
Medicare patients
145
Services billed
3,750

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5063$409,428
HizentraImmun Glob G(Igg)/Pro/Iga 0-5023$398,995
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5023$206,887
Dupixent PenDupilumab11$40,686
Breo ElliptaFluticasone/Vilanterol31$14,205
Advair HfaFluticasone Propion/Salmeterol28$11,762
Arnuity ElliptaFluticasone Furoate23$6,538
Epinephrine27$5,040
Zafirlukast28$2,896
Ipratropium Bromide60$2,305
Desloratadine12$1,735
Azelastine Hcl41$1,281
Albuterol Sulfate HfaAlbuterol Sulfate35$984
Montelukast Sodium32$495
Levocetirizine Dihydrochloride31$338

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen, Hizentra$36$808,42386 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy/ immunology providers in New Jerseyon file to place this against a meaningful peer group, so we don't.

Other allergy/ immunology in Hackensack

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →